A Phase I, Randomized, Single-Blind, Three-Period Cross-Over, Placebo-Controlled, Single Oral Dose, Dose-Escalation (Part 1), Fixed Sequence, and Repeat Dose (Part 2) Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Losmapimod in Healthy Japanese Subjects.
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Losmapimod (Primary)
- Indications Acute coronary syndromes
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 08 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Sep 2012 Planned number of patients changed from 12 to 36 as reported by ClinicalTrials.gov.